Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism jaw tumor syndrome
Aromatase inhibitor therapy improved progesterone-resistant menorrhagia in a patient with hyperparathyroidism–jaw tumor syndrome.
Erin F. Wolff, M.D., Micah J. Hill, D.O., William F. Simonds, M.D., James H. Segars, M.D.
Volume 98, Issue 6, Pages 1616-1619, December 2012
To describe the clinical management of menorrhagia in a woman with hyperparathyroidism-jaw tumor syndrome (HPT-JT).
Large translation research hospital.
A 26-year-old nulligravid woman with familial HPT-JT presented with life-long menorrhagia resistant to progesterone IUD therapy and a desire for fertility.
Aromatase inhibitor therapy.
Main Outcome Measures:
Clinical response to therapy and pregnancy.
Imaging demonstrated an enlarged endometrial lining and thickening of the junctional zone. At operative hysteroscopy, multiple atypical endometrial polyp-like lesions filled the entire uterine cavity and were removed. Histologic evaluation demonstrated the lesions to be adenomyomas with an abundance of aromatase expression. Postoperative treatment included an aromatase inhibitor. The patient’s menorrhagia, which had previously been resistant to progesterone IUD therapy, resolved with the aromatase inhibitor. After ten months of this treatment, the aromatase inhibitor was discontinued and a repeat hysteroscopy revealed a markedly improved uterine cavity. The patient subsequently became pregnant on her first natural cycle and delivered a healthy term infant.
Aromatase inhibitors may represent a novel treatment for benign uterine pathology in HPT-JT.